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Interleukin 7 (IL-7), which is required for T cell survival, was previously found in lymphoid tissues. In this issue
of Immunity, Sawa et al. (2009) have identified the liver as a new source of IL-7.Adjuvants promote the primary T cell
response as well as the conversion of
T cells from naive to memory. In this issue
of Immunity, Sawa et al. (2009) show that
a number of adjuvants that act via Toll-
like receptors (TLRs) can induce produc-
tion of hepatocyte IL-7. The study mainly
focuses on lipopolysaccharide (LPS) but
also shows that the liver produces IL-7 in
response to other TLR stimuli, including
CpG, poly(I-C), imiquimod, zymosan, and
Complete Freund’s adjuvant (CFA).
IL-7 is required for survival of most T cell
subsets, and its expression has been
proposed to be important for regulating
T cell numbers. Production of IL-7 by
stromal cells has previously been thought
to beconstitutive, and therefore consump-
tionof IL-7byTcells via their IL-7 receptors
has been proposed to play an important
role in T cell homeostasis (Mazzucchelli
and Durum, 2007). Although this constitu-
tive IL-7productionmodel remains tenable
in lymphoid organs, Sawa et al. now show
thathepatocytescanproduce immunolog-
ically stimulatory amounts of IL-7 in
response to adjuvants that act via TLRs
(Figure 1). IL-7 has therefore become, in
a sense, one of the acute-phase reactants.
The hepatocyte response is distinct from
spleen and lymph node stromal cells,
which did not upregulate IL-7 in response
to TLR ligands.
Proof that the liver was the IL-7 source
primarily relied on clever application of
hydrodynamic DNA injection, which is
selectively taken up by hepatocytes.
Sawa et al. used this method to introduce
interfering RNA for IL-7, which in turn
blockedanumberofTLR-mediatedeffects
on T cells, demonstrating that liver was the
major IL-7 source. TLR effects mediated
by hepatocyte IL-7 included enhanced
CD4+ and CD8+ T cell survival (Figure 1),
augmentedCTL activity, and experimental320 Immunity 30, March 20, 2009 ª2009 Elseautoimmune encephalomyelitis (EAE) via
promotion of a Th17 response. In the
absence of TLR ligands, the liver did not
appear to be a major contributor of IL-7
to T cell survival; under normal conditions,
IL-7 is thought to be provided by stromal
cells in lymphoid organs, although this
remains to be rigorously proven.
The hepatocyte response was shown
to be indirect (Figure 1). An intermediate,
undefined cell responded to TLR ligands
and, via the Toll/interleukin-1R homolo-
gous-domain-containing adaptor protein
inducing interferon-beta (TRIF) signaling
pathway, induced synthesis of type I inter-
feron, which in turn acted on hepatocytes
eliciting IL-7 production. IL-7 induction
had been reported to be driven in vitro by
IFN-g (Ariizumi et al., 1995; Oshima et al.,
2004) and tumor necrosis factor (TNF-a)
(Weitzmannet al., 2000) and in vivo by ker-
atinocyte growth factor (KGF) (Min et al.,
2002) or IL-6 (Sawa et al., 2006). Although
IFN-g induces IL-7 production from
thymic cell lines, from our experience it
does not induce it in the liver, and there-
fore the effect is apparently restricted to
type I IFNs, i.e., the innate rather than the
adaptive immune response.
It was not determined where T cells
encountered this hepatic IL-7 elicited by
adjuvants. The IL-7 effects included
increased T cell numbers in spleen and
lymph node, as well as liver. It is possible
that T cells circulate through liver and
encounter IL-7 near the hepatocyte, in
paracrine fashion. It seems less likely
that hepatic IL-7 acted at a distance from
the liver: the serum amounts reported in
the study, although elevated, appear too
low to have a biological effect. In addition,
it has not been determined where T cells
encounter IL-7 under normal circum-
stances, and this is an important issue
that remains to be addressed.vier Inc.The increase in T cells was not accom-
panied by increased BrdU incorporation,
suggesting that IL-7 did not increase
T cell proliferation, which in their study
was already quite vigorous in some T cell
subsets. Thus, T cells proliferate and die
under normal conditions, and the TLR-
hepatic-IL-7 effect is to protect from cell
death. In contrast, pharmacological doses
of IL-7 can induce substantial cell division.
This difference probably reflects the
concentration of IL-7; low IL-7 amounts,
as in the adjuvant effect, promote survival
but not cell division, whereas high doses
induce both survival and cell cycling.
Thehepatic IL-7 increasedidnotenhance
primary T cell responses to antigen. This is
consistent with most previous studies,
which show little effect of IL-7 on primary
responses, in part because of the loss of
IL-7 receptor expression on activated
T cells. However, hepatic IL-7 was shown
to prolong the CTL and IFN-g responses
promotedbyTLR ligands,perhapsbecause
IL-7 receptor reappears on memory T cells.
The reported liver response to LPS was
transient. Il7 mRNA message peaked at
3 hr and was back to baseline by 6 hr;
the numbers of T cells peaked on day 3
and returned to normal levels at day 6.
Despite the transience of LPS-induced
IL-7, a long-lasting effect was observed
in the EAE model, in which hepatic IL-7
exacerbated disease weeks later. There
could be several explanations for an
enduring effect of IL-7 in EAE. One possi-
bility is that CFA and pertussis toxin are
used in EAE, rather than LPS, and perhaps
they elicit a more durable hepatic IL-7
expression. Another intriguing possibility
is that there is something peculiarly autor-
eactive about the T cells that expand in the
presence of IL-7. Perhaps the cells that
liver IL-7 promotes are slightly more self
reactive. It has often been noted that
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PreviewsFigure 1. Triggering of Several Different TLRs in an Unknown Cell Type Induces Type I IFN
Expression via the TRIF Signaling Pathway
Type I IFN acts on hepatocytes, inducing IL-7 expression and release. IL-7 then prolongs the survival
of naive and memory T cells.lymphopenia promotes autoimmunity,
and in lymphopenia, IL-7 would be more
abundant. Fortunately, patients treated
with IL-7 have not, as yet, shown autoim-
mune sequelae, and clinicians are very
cognizant of this possible risk. However,
previous studies have connected IL-7
with EAE (Bebo et al., 2000) and multiple
sclerosis (Traggiai et al., 2001).
The IL-7 protein cannot be visualized by
immunohistochemistry in tissues because
protein expression is too low. For this
reason, there remain many fundamental
questions, including those about the sites
in which T cells encounter IL-7, as well as
regulation of protein amounts. We do not
know whether mRNA expression is the
only mechanism controlling the proteinamounts. There could be constraints on
translation as there are for IL-15. We also
do not knowwhat becomes of IL-7 protein
after it is produced in tissues. Although
a small protein such as IL-7 would have
a very short half-life in serum, it is possible
that IL-7 in tissues associates with extra-
cellular matrix and could be available for
weeks—this is another potential explana-
tion of how a transient increase in IL-7
transcripts could generate a sustained
supply of protein. Another unrelated but
vexing question is why IL-7 antibodies
have so little effect in vivo, whereas
dramatic effects are shown by transfer
of T cells into Il7/ recipients. Fresh
approaches are needed to probe this
essential protein.Immunity 3Onto the playing field of adjuvanticity
and autoimmunity, the study by Sawa
et al. introduces important new partici-
pants: IFNs, hepatocytes, and IL-7. It is
the game plan that remains elusive.
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